TAK Short Volume
Takeda Pharmaceutical Company Limited (TAK) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, with a market capitalization near $58.93B, listed on NYSE, employing roughly 47,029 people, carrying a beta of 0.09 to the broader market. Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. Led by Julie So-Young Kim, public since 2010-01-05.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-10-14
- Short Volume
- 655.9K
- Total Volume
- 1.8M
- Short %
- 37.38%
- 30-Day Avg Short %
- 36.60%
Showing 30 days of FINRA short volume data for Takeda Pharmaceutical Company Limited.
Learn how short volume is reported and how to read the data →
Frequently asked TAK short volume questions
- What is the daily TAK short volume?
- As of Oct 14, 2026, Takeda Pharmaceutical Company Limited (TAK) short volume is 655.9K shares against 1.8M total reported volume, or 37.38% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is TAK short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does TAK short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.